Xyphos Biosciences, Inc., is a pre-clinical stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The Company’s proprietary technology platform produces next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies comprised of a universal, engineered T-cell and attached effector control molecules (tumor-specific antibodies the Company calls “MicAbodies” and function supporting agents the Company calls “MicAdaptors”). Xyphos’ CAR-T therapies are designed to achieve a complete, specific and durable immune response to target and cure both hematological and solid tumors. Xyphos believes its platform, Advanced Cellular Control by Engineered Ligands (“ACCEL”), is a significant improvement upon current cell therapies. The Company’s vision is to leverage the ACCEL platform to transform cancer treatment and to deliver patient cures in a wide variety of malignancies.

Contact Xyphos Biosciences
Visit Website